Intuitive Surgical Founder Joins SS Innovations Board

Talk about a perfect match. The “father of surgical robots”—a.k.a., Fredric Moll, M.D., is joining SS Innovations International Inc.’s Board of Directors as vice chairman. 
 
Dr. Moll brings a wealth of industry experience and expertise to the board, having supervised the development and commercialization of the da Vinci surgical robotic system. He most recently served as chief development officer for Johnson & Johnson Medical Devices Companies from April 2019 to March 2023. Dr. Moll was a co-founder, chairman, and CEO of Auris Health Inc., a robotics medical device company that was acquired by Johnson & Johnson in 2019. Dr. Moll is also the founding partner of Sonder Capital Management LLC, a healthcare venture capital investment firm. He served on the board of Shockwave Medical Inc. from March 2011 through its acquisition by Johnson & Johnson in May 2024. He was an early investor in Avra Medical Robotics and is a current investor in SS Innovations.
 
“The strength and caliber of Dr. Moll’s leadership is peerless, and he will be a tremendous addition to our Board of Directors,” SS Innovations Chairman/CEO Dr. Sudhir Srivastava said . “Joining us during the most robust phase of global growth to date, his appointment is perfectly timed. As a pioneer in robotic surgery, Dr. Moll offers a unique perspective and legacy as well as superior insight on the direction and promising future of the industry and SS Innovations.”
 
Earlier this year, SS Innovations launched the SSI Mantra 3, the newest and most advanced version of its surgical robotic system. The SSi Mantra 3 provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more while engaging with surgeons and surgical teams to improve safety and efficiency during procedures. The regulatory approval process from the U.S. Food and Drug Administration (FDA) is already underway, and SS Innovations anticipates receiving market approval later next year.

“I am excited to help with SS Innovation’s mission to bring the benefits of robotic surgery not just to more people in the United States but also to the rest of the world. This technology should be available to everyone on the planet, and I believe the company successfully addresses the reasons why others have not yet been able to do so,” Moll stated. “It is much more affordable than what is out there now without sacrificing any clinical capabilities. It even has capabilities such as in cardiac that no one else even has. I also believe that the system’s proven telesurgery capabilities as well as its related teaching and proctoring tools will prove invaluable.”

Supporting advanced, affordable, and accessible robotic surgery, the SSi Mantra features a modular arm configuration, 3D 4K vision open-console design, and superior ergonomics, enabling the system to engage with the surgeon and surgical teams to improve safety and efficiency during procedures. The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 80 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union.

SS Innovations International develops surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra” its wide range of surgical instruments capable of supporting various surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally.